Results 141 to 150 of about 9,340 (184)

Comparative effectiveness of dupilumab versus mepolizumab and benralizumab in asthma: a multinational retrospective cohort study.

Journal of Allergy and Clinical Immunology: In Practice
BACKGROUND Several biologic agents have been approved for asthma treatment. However, previous comparative effectiveness studies have been indirect treatment comparisons or restricted in geographical scope.
Chun-Tse Hung, Yu-Chien Hung, Chi-won Suk   +2 more
semanticscholar   +1 more source

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

Arthritis & Rheumatology
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects.
Michael E. Wechsler, J. Silver, G. Wolff, Robert G. Price, R. Verghis, P. F. Weller, P. Merkel, P. Khoury   +7 more
semanticscholar   +1 more source

Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization.

NEJM Evidence
BACKGROUND Admission to hospital with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is associated with a high risk of morbidity and mortality.
Cara Flynn, Hamish J. C. McAuley, O. Elneima, H. Aung, W. Ibrahim, Thomas J C Ward, M. Bourne, T. Thornton, V. Mistry, Hannah R Gilbert, G. Waheed, Adam K A Wright, R. A. Evans, Michael C Steiner, C. L. Brookes, C. Brightling, Neil J Greening   +16 more
semanticscholar   +1 more source

Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children: A Secondary Analysis of a Randomized Clinical Trial.

JAMA pediatrics
Importance While biologic therapies targeting type 2 (T2) inflammation reduce acute exacerbation rates in children with asthma and T2 inflammation, exacerbations still occur, and the underlying molecular mechanisms are poorly defined.
Matthew C. Altman, Tomasz Janczyk, R. C. Murphy, N. Jayavelu, A. Calatroni, M. Kattan, M. Gill, Jeffrey R. Stokes, Andrew H. Liu, G. K. Khurana Hershey, M. Sherenian, Rajesh Kumar, Rachel G Robison, R. Gruchalla, George T. O'Connor, E. Zoratti, S. Teach, Susan V. Lynch, K. Dill-McFarland, P. Becker, A. Togias, J. Gern, L. Bacharier, William W. Busse, Daniel J. Jackson   +24 more
semanticscholar   +1 more source

Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies

Biomolecules
Eosinophilic granulomatosis with polyangiitis (EGPA) is a necrotizing vasculitis characterized by extravascular granulomas and eosinophilia in both blood and tissues.
Mayu Shiomi, R. Watanabe, Ryuhei Ishihara, Sayaka Tanaka, Takashi Nakazawa, M. Hashimoto   +5 more
semanticscholar   +1 more source

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.

Annals of Allergy, Asthma & Immunology
BACKGROUND Some patients with severe asthma have overlapping allergic and eosinophilic phenotypes and may be eligible for anti-eosinophilic or anti-IgE biologics.
Jason K Lee, S. Pollard, Mark C Liu, Florence Schleich, G. Pelaia, Carlos Almonacid, L. Heaney, Rekha Chaudhuri, R. Alfonso-Cristancho, Lingjiao Zhang, A. Maxwell, Peter Howarth   +11 more
semanticscholar   +1 more source

Effect of Mepolizumab in airway's remodelling in patients with late-onset severe asthma with an eosinophilic phenotype.

Journal of Allergy and Clinical Immunology
BACKGROUND Clinical trials and real-world experience have provided evidence for the clinical benefit of mepolizumab, an anti-IL-5 biologic, in severe asthma.
K. Domvri, I. Tsiouprou, P. Bakakos, P. Steiropoulos, Konstantinos Katsoulis, Konstantinos Kostikas, Katerina M. Antoniou, A. Papaioannou, N. Rovina, P. Katsaounou, T. Papamitsou, Nicoleta Pastelli, S. Tryfon, E. Fouka, Despoina Papakosta, S. Loukides, Konstantinos Porpodis   +16 more
semanticscholar   +1 more source

Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials.

Respiratory Medicine
BACKGROUND Eosinophilic chronic obstructive pulmonary disease (eCOPD), characterized by type 2 inflammation, is an emerging target for biologic therapies.
Philipp Suter, Robert Greig, R. Chan, Brian J. Lipworth   +3 more
semanticscholar   +1 more source

Mepolizumab in patients with lymphoid variant hypereosinophilic syndrome: a multi-center prospective study.

Journal of Allergy and Clinical Immunology
BACKGROUND Hypereosinophilic syndrome (HES) is characterized by blood and tissue hypereosinophilia causing organ damage and/or dysfunction. Mepolizumab, an anti-IL-5 antibody, has recently been approved in this indication.
Julien Catherine, S. Karimi, Laurent Dewispelaere, C. Lelubre, L. Schandené, F. Roufosse   +5 more
semanticscholar   +1 more source

Mepolizumab

Reactions Weekly, 2023
  +5 more sources